By Karen Roman VERAXA Biotech AG said it has a securities purchase agreement with an institutional investor for $27.5 million, separate to a $50 million share purchase agreement with Lincoln Park Capital Fund. The company also applied for a Nasdaq...

By Daniella Parra Imviva Biotech said data showed its CTA313 drug resulted in 50% of patients going into remission for systemic lupus. Many patients experience incomplete responses, recurrent flares and long-term treatment-related toxicity, it said. “The clinical activity observed with...

By Daniella Parra SkylineDx shared new findings in cutaneous squamous cell carcinoma (CSCC) research that could help improve early risk detection and treatment strategies for skin cancer patients worldwide. Researchers developed a new gene-expression signature, SCCore GEP, that may better...

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the recent outbreak of the hantavirus on a cruise ship highlights the need for broad-spectrum  antiviral drugs such as NV-387. The hantavirus gets into the lungs through droplets of cough or spit...

By Daniella Parra Glucotrack, Inc. (Nasdaq: GCTK) said it has submitted an Investigational Device Exemption application to the FDA to begin a U.S. clinical study for its fully implantable continuous blood glucose monitoring technology. The company said it is designed...

By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the FDA granted “Orphan Drug Designation” (ODD) to its clinical-stage, antiviral drug NV-387 for the treatment of measles, giving the company seven years of market exclusivity after approval and access to tax...

By Karen Roman Agilent Technologies, Inc. (NYSE: A) said it designated Michael Buckner as Chief Legal Officer, having previously served at Danaher as Vice President, Deputy General Counsel, and Chief M&A Counsel. Mr. Buckner has nearly 30 years of experience...

By Daniella Parra Glucotrack, Inc. (Nasdaq: GCTK) shared a study highlighting the long-term accuracy of its implantable blood glucose monitoring system as it moves closer to FDA clinical development and eventual commercialization, it said. The results also align with earlier...

By Daniella Parra CareDx (Nasdaq: CDNA) said it signed a definitive agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company, for up to $260 million and will close in the third quarter. Naveris makes NavDx, a blood-based test that...

By Exec Edge Editorial Staff Most patients never meet their anesthesiologist before surgery day. They sign a consent form, may ask a few questions in pre-op, and wake up in recovery with only a hazy memory of the clinician who...